扑热息痛 IV 市场机会、成长动力、产业趋势分析与预测 2025 - 2034

2024年全球扑热息痛IV市场价值为8.607亿美元，预计2025年至2034年将以4.2%的年复合成长率(CAGR)增长。口服药物时。它对于治疗术后恢復、严重感染以及患有胃肠道併发症的患者特别有效。

医院环境对快速止痛的需求，特别是术后和创伤护理，是推动市场成长的关键因素。由于成瘾和其他副作用的风险，越来越多的患者寻求阿片类药物的替代品，非阿片类止痛药物（如扑热息痛 IV）的受欢迎程度激增。它能够有效缓解疼痛，同时最大限度地减少副作用，使其成为各种临床环境的首选。

扑热息痛 IV 通常在医院和诊所用于控制中度至重度疼痛，并在口服或直肠药物不适合时退烧。它是多模式镇痛方案的关键组成部分，特别是在手术环境中，它在减少对阿片类镇痛药的需求和限制阿片类药物相关併发症的风险方面发挥着至关重要的作用。

市场分为两个主要应用类别：手术和非手术。由于扑热息痛 IV 在术后疼痛管理的使用不断增加，手术部分在 2024 年占据了最大份额。由于人口老化和慢性病的流行，全球手术数量不断增加，进一步支持了这一领域的成长。

在医疗适应症方面，扑热息痛静脉注射市场分为疼痛管理和退烧（发烧）。疼痛管理占据最大份额，受益于在术后护理、急诊室和创伤护理中越来越多地采用非阿片类药物替代品来缓解疼痛。向更安全的疼痛管理策略的转变显着促进了细分市场的成长。

市场也按最终用途进行细分，其中医院和诊所是主导类别。这些设定受益于扑热息痛 IV 提供的快速作用和受控剂量，这使其成为治疗急性疼痛和术后恢復的理想选择。外科手术数量的增加以及对有效疼痛管理解决方案的更加关注预计将推动该领域的持续成长。

2024年，由于对有效疼痛管理的需求不断增加，特别是在手术和术后护理方面，美国在北美扑热息痛静脉注射市场占据了很大份额。美国市场的成长得益于手术数量的增加、非阿片类止痛药的日益普及以及领先製药公司在该地区的强大影响力。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 疼痛和发烧的盛行率上升
    • 外科手术数量不断增加
    • 静脉给药的优点
    • 重症监护环境中越来越多的采用
  • 产业陷阱与挑战
    • 与口服替代品相比成本较高
    • 副作用和健康风险
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按应用划分，2021 - 2034 年

• 主要趋势
• 外科
• 非手术

第 6 章：市场估计与预测：按指标划分，2021 - 2034 年

• 主要趋势
• 疼痛管理
• 发热

第 7 章：市场估计与预测：按最终用途，2021 - 2034 年

• 主要趋势
• 医院和诊所
• 门诊手术中心 (ASC)
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2034

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 9 章：公司简介

• AdvaCare Pharma
• Altan Pharma
• B. Braun SE
• Cipla Inc.
• Criticine Care
• Fresenius Kabi
• GNova Biotech
• Lupin
• Mallinckrodt Pharmaceuticals
• Pfizer
• Solitaire Pharmacia
• Unital Pharmaceuticals

The Global Paracetamol IV Market was valued at USD 860.7 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2034. Paracetamol IV, known for its strong analgesic and antipyretic properties, is widely used when oral medication is not an option. It is especially effective in managing post-surgical recovery, severe infections, and for patients with gastrointestinal complications.

The demand for fast-acting pain relief in hospital settings, particularly for post-operative and trauma care, is a key factor driving the market growth. As more patients seek alternatives to opioids due to the risks of addiction and other side effects, the popularity of non-opioid pain treatments, such as paracetamol IV, has surged. Its ability to provide effective pain relief while minimizing adverse effects has made it a preferred choice in various clinical settings.

Paracetamol IV is commonly used in hospitals and clinics to manage moderate to severe pain and reduce fever when oral or rectal medications are not suitable. It is a key component of multimodal analgesia protocols, particularly in surgical settings, where it plays a crucial role in reducing the need for opioid-based analgesics and limiting the risk of opioid-related complications.

The market is divided into two primary application categories: surgical and non-surgical. The surgical segment accounted for the largest share in 2024, driven by the growing use of paracetamol IV in post-operative pain management. The increasing number of surgeries worldwide, fueled by a rising aging population and the prevalence of chronic diseases, further supports the growth of this segment.

In terms of medical indications, the paracetamol IV market is split into pain management and fever reduction (pyrexia). Pain management holds the largest share, benefiting from the growing adoption of non-opioid alternatives for pain relief in post-operative care, emergency rooms, and trauma care. The shift toward safer pain management strategies has significantly boosted segment growth.

The market is also segmented by end-use, with hospitals and clinics being the dominant category. These settings benefit from the rapid action and controlled dosage provided by paracetamol IV, which makes it an ideal choice for managing acute pain and post-surgical recovery. The increasing number of surgical procedures and a greater focus on effective pain management solutions are expected to drive continued growth in this segment.

In 2024, the U.S. held a substantial share of the North America paracetamol IV market, driven by an increased demand for efficient pain management, particularly in surgical and post-operative care. The market growth in the U.S. is supported by a rise in the number of surgeries, the growing adoption of non-opioid pain relief, and the strong presence of leading pharmaceutical companies in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of pain and fever
    • 3.2.1.2 Growing number of surgical procedures
    • 3.2.1.3 Advantages of intravenous administration
    • 3.2.1.4 Growing adoption in critical care settings
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost compared to oral alternatives
    • 3.2.2.2 Side effects and health risks
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Surgical
• 5.3 Non-surgical

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
• 6.3 Pyrexia

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Ambulatory Surgical Centers (ASCs)
• 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AdvaCare Pharma
• 9.2 Altan Pharma
• 9.3 B. Braun SE
• 9.4 Cipla Inc.
• 9.5 Criticine Care
• 9.6 Fresenius Kabi
• 9.7 GNova Biotech
• 9.8 Lupin
• 9.9 Mallinckrodt Pharmaceuticals
• 9.10 Pfizer
• 9.11 Solitaire Pharmacia
• 9.12 Unital Pharmaceuticals